Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease

Yen Ying Lim; Paul Maruff; Naoki Kaneko; James Doecke; Christopher Fowler; Victor L Villemagne; Takashi Kato; Christopher C. Rowe; Yutaka Arahata; Shinichi Iwamoto; Kengo Ito; Koichi Tanaka; Katsuhiko Yanagisawa; Colin L Masters; Akinori Nakamura

doi:10.3233/JAD-200475

Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease

Yen Ying Lim, Paul Maruff, Naoki Kaneko, James Doecke, Christopher Fowler, Victor L Villemagne, Takashi Kato, Christopher C. Rowe, Yutaka Arahata, Shinichi Iwamoto, Kengo Ito, Koichi Tanaka, Katsuhiko Yanagisawa, Colin L Masters, Akinori Nakamura

Psychology

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Background:
Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationship with clinical outcomes remains unclear.

Objective:
We aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts.

Methods:
Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and the National Centre for Geriatrics and Gerontology (NCGG) study had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood samples. We derived a high-performance plasma Aβ composite biomarker by immunoprecipitation with mass-spectrometry.

Results:
Both continuous and categorical measures of the plasma Aβ composite biomarker were significantly related to decline in episodic memory and executive function. The magnitude of effects of the plasma Aβ composite on episodic memory and executive function were comparable to that observed for the effects of PET Aβ levels on these same outcome measures.

Conclusion:
Several plasma Aβ biomarkers have been developed, but none have yet been applied to investigate their relationship with cognitive outcomes. Our results have important implications for the use of this biomarker in the detection of at-risk individuals.

Original language	English
Pages (from-to)	1057-1065
Number of pages	9
Journal	Journal of Alzheimer's Disease
Volume	77
Issue number	3
DOIs	https://doi.org/10.3233/JAD-200475
Publication status	Published - 29 Sept 2020

Keywords

amyloid-β
cognition
memory
plasma
plasma biomarker
preclinical Alzheimer's disease

Access to Document

10.3233/JAD-200475

Biological, genetic and lifestyle moderators of Alzheimer's pathogenesis, cognitive decline and clinical disease progression
Lim, Y. Y.
National Health and Medical Research Council (NHMRC) (Australia)
4/05/20 → 31/12/22
Project: Research

Cite this

Lim, Y. Y., Maruff, P., Kaneko, N., Doecke, J., Fowler, C., Villemagne, V. L., Kato, T., Rowe, C. C., Arahata, Y., Iwamoto, S., Ito, K., Tanaka, K., Yanagisawa, K., Masters, C. L., & Nakamura, A. (2020). Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 77(3), 1057-1065. https://doi.org/10.3233/JAD-200475

@article{1814bd3a4d154286b9bc7e2363a71a58,

title = "Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease",

abstract = "Background:Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationship with clinical outcomes remains unclear.Objective:We aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts.Methods:Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and the National Centre for Geriatrics and Gerontology (NCGG) study had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood samples. We derived a high-performance plasma Aβ composite biomarker by immunoprecipitation with mass-spectrometry.Results:Both continuous and categorical measures of the plasma Aβ composite biomarker were significantly related to decline in episodic memory and executive function. The magnitude of effects of the plasma Aβ composite on episodic memory and executive function were comparable to that observed for the effects of PET Aβ levels on these same outcome measures.Conclusion:Several plasma Aβ biomarkers have been developed, but none have yet been applied to investigate their relationship with cognitive outcomes. Our results have important implications for the use of this biomarker in the detection of at-risk individuals.",

keywords = "amyloid-β, cognition, memory, plasma, plasma biomarker, preclinical Alzheimer's disease",

author = "Lim, {Yen Ying} and Paul Maruff and Naoki Kaneko and James Doecke and Christopher Fowler and Villemagne, {Victor L} and Takashi Kato and Rowe, {Christopher C.} and Yutaka Arahata and Shinichi Iwamoto and Kengo Ito and Koichi Tanaka and Katsuhiko Yanagisawa and Masters, {Colin L} and Akinori Nakamura",

year = "2020",

month = sep,

day = "29",

doi = "10.3233/JAD-200475",

language = "English",

volume = "77",

pages = "1057--1065",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "IOS Press",

number = "3",

}

Lim, YY, Maruff, P, Kaneko, N, Doecke, J, Fowler, C, Villemagne, VL, Kato, T, Rowe, CC, Arahata, Y, Iwamoto, S, Ito, K, Tanaka, K, Yanagisawa, K, Masters, CL & Nakamura, A 2020, 'Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease', Journal of Alzheimer's Disease, vol. 77, no. 3, pp. 1057-1065. https://doi.org/10.3233/JAD-200475

TY - JOUR

T1 - Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease

AU - Lim, Yen Ying

AU - Maruff, Paul

AU - Kaneko, Naoki

AU - Doecke, James

AU - Fowler, Christopher

AU - Villemagne, Victor L

AU - Kato, Takashi

AU - Rowe, Christopher C.

AU - Arahata, Yutaka

AU - Iwamoto, Shinichi

AU - Ito, Kengo

AU - Tanaka, Koichi

AU - Yanagisawa, Katsuhiko

AU - Masters, Colin L

AU - Nakamura, Akinori

PY - 2020/9/29

Y1 - 2020/9/29

N2 - Background:Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationship with clinical outcomes remains unclear.Objective:We aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts.Methods:Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and the National Centre for Geriatrics and Gerontology (NCGG) study had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood samples. We derived a high-performance plasma Aβ composite biomarker by immunoprecipitation with mass-spectrometry.Results:Both continuous and categorical measures of the plasma Aβ composite biomarker were significantly related to decline in episodic memory and executive function. The magnitude of effects of the plasma Aβ composite on episodic memory and executive function were comparable to that observed for the effects of PET Aβ levels on these same outcome measures.Conclusion:Several plasma Aβ biomarkers have been developed, but none have yet been applied to investigate their relationship with cognitive outcomes. Our results have important implications for the use of this biomarker in the detection of at-risk individuals.

AB - Background:Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationship with clinical outcomes remains unclear.Objective:We aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts.Methods:Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and the National Centre for Geriatrics and Gerontology (NCGG) study had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood samples. We derived a high-performance plasma Aβ composite biomarker by immunoprecipitation with mass-spectrometry.Results:Both continuous and categorical measures of the plasma Aβ composite biomarker were significantly related to decline in episodic memory and executive function. The magnitude of effects of the plasma Aβ composite on episodic memory and executive function were comparable to that observed for the effects of PET Aβ levels on these same outcome measures.Conclusion:Several plasma Aβ biomarkers have been developed, but none have yet been applied to investigate their relationship with cognitive outcomes. Our results have important implications for the use of this biomarker in the detection of at-risk individuals.

KW - amyloid-β

KW - cognition

KW - memory

KW - plasma

KW - plasma biomarker

KW - preclinical Alzheimer's disease

U2 - 10.3233/JAD-200475

DO - 10.3233/JAD-200475

M3 - Article

SN - 1387-2877

VL - 77

SP - 1057

EP - 1065

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

IS - 3

ER -

Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease

Abstract

Keywords

Access to Document

Projects

Biological, genetic and lifestyle moderators of Alzheimer's pathogenesis, cognitive decline and clinical disease progression

Cite this